Cargando…

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study

Pivotal trials showed the effectiveness of the monoclonal antibody ocrelizumab in relapsing and progressive multiple sclerosis (MS). However, data on everyday practice in MS patients and markers of treatment effectiveness are scarce. We aimed to collect real-world data from ocrelizumab-treated MS pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanzillo, Roberta, Carotenuto, Antonio, Signoriello, Elisabetta, Iodice, Rosa, Miele, Giuseppina, Bisecco, Alvino, Maniscalco, Giorgia Teresa, Sinisi, Leonardo, Romano, Felice, Di Gregorio, Maria, Lavorgna, Luigi, Trojsi, Francesca, Moccia, Marcello, Fratta, Mario, Capasso, Nicola, Dubbioso, Raffaele, Petracca, Maria, Spiezia, Antonio Luca, Gallo, Antonio, Petruzzo, Martina, De Angelis, Marcello, Bonavita, Simona, Lus, Giacomo, Tedeschi, Gioacchino, Brescia Morra, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029051/ https://www.ncbi.nlm.nih.gov/pubmed/35456175 http://dx.doi.org/10.3390/jcm11082081

Ejemplares similares

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
por: Moccia, Marcello, et al.
Publicado: (2022)

Assessing disability and relapses in multiple sclerosis on tele-neurology
por: Moccia, Marcello, et al.
Publicado: (2020)

Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review
por: De Angelis, Marcello, et al.
Publicado: (2021)

Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2019)

Google Maps Timeline: An open-access digital tool to monitor walking abilities in people with multiple sclerosis
por: Caliendo, Daniele, et al.
Publicado: (2023)

Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
por: Capasso, Nicola, et al.
Publicado: (2022)

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
por: Russo, Antonio, et al.
Publicado: (2020)

AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature
por: Spiezia, Antonio Luca, et al.
Publicado: (2022)

A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple Sclerosis
por: Reia, Antonio, et al.
Publicado: (2021)

Functional Plasticity of the Visual System in Multiple Sclerosis
por: Gallo, Antonio, et al.
Publicado: (2015)

Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis
por: Petracca, Maria, et al.
Publicado: (2021)

Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials
por: Moccia, Marcello, et al.
Publicado: (2020)

Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak
por: Carotenuto, Antonio, et al.
Publicado: (2021)

Social Media and Multiple Sclerosis in the Posttruth Age
por: Lavorgna, Luigi, et al.
Publicado: (2017)

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
por: De Angelis, Marcello, et al.
Publicado: (2020)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2021)

Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions
por: Vola, Elena Augusta, et al.
Publicado: (2021)

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
por: Moccia, Marcello, et al.
Publicado: (2020)

Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis
por: Cennamo, Gilda, et al.
Publicado: (2020)

Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015
por: Moccia, Marcello, et al.
Publicado: (2017)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Disability assessment using Google Maps
por: Lavorgna, Luigi, et al.
Publicado: (2021)

Correction to: Disability assessment using Google Maps
por: Lavorgna, Luigi, et al.
Publicado: (2021)

Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience
por: Rosa, Laura, et al.
Publicado: (2022)

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
por: Abbadessa, Gianmarco, et al.
Publicado: (2021)

Retinal and Choriocapillary Vascular Changes in Early Stages of Multiple Sclerosis: A Prospective Study
por: Montorio, Daniela, et al.
Publicado: (2021)

Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data
por: Moccia, Marcello, et al.
Publicado: (2021)

Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery
por: Moccia, Marcello, et al.
Publicado: (2019)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study
por: Rosa, Laura, et al.
Publicado: (2022)

Public Engagement and Neurology: An Update
por: Lavorgna, Luigi, et al.
Publicado: (2021)

Health-Related Coping and Social Interaction in People with Multiple Sclerosis Supported by a Social Network: Pilot Study With a New Methodological Approach
por: Lavorgna, Luigi, et al.
Publicado: (2017)

Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis
por: Novarella, Federica, et al.
Publicado: (2022)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

A two-year longitudinal study of retinal vascular impairment in patients with amnestic mild cognitive impairment
por: Criscuolo, Chiara, et al.
Publicado: (2022)

Corrigendum: A two-year longitudinal study of retinal vascular impairment in patients with amnestic mild cognitive impairment
por: Criscuolo, Chiara, et al.
Publicado: (2023)

Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2019)

Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10
por: Moccia, Marcello, et al.
Publicado: (2019)

Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
por: Abbadessa, Gianmarco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jq7la5loufvnglquappo3jke9h